Lung Cancer Genomic Testing Market Size, Share & Trends Analysis Report By Type (Products, Services), By Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Fluorescence in Situ Hybridization), By Sample Type (Tissue biopsy, Liquid biopsy), By Panel Type (Multi-Gene panels, Single-Gene panels), By End-User (Research organizations, Hospitals/Clinics, Diagnostic Laboratories) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Market Overview

The global lung cancer genomic testing market size was valued at USD 1.21 billion in 2023. It is estimated to reach USD 2.47 billion by 2032, growing at a CAGR of 8% during the forecast period (2024–2032). In recent years, there has been an exponential rise in the cases of lung cancer owing to several factors like smoking, a rise in air pollution, etc. This is anticipated to drive the global lung cancer genomic testing market. Furthermore, advancements in genomic testing to enhance their efficiency are estimated to create opportunities for global market expansion.

Highlights

• Products dominate the type segment.
• Polymerase Chain Reaction (PCR) dominates the technology market.
• Hospitals dominate the end-user segment.
• North America is the highest shareholder in the global market.

Market overview

Lung Cancer Genomic Testing, also known as Lung Cancer Genetic Testing, is a technique that examines the genetic makeup of lung cancer cells in order to detect specific mutations or abnormalities that can be targeted with customized therapies. This testing is critical for patients with non-small cell lung cancer (NSCLC) as it can assist in uncovering genetic alterations that can be targeted with specific medications, resulting in more successful treatment and fewer side effects. Tissue samples from a lung tumor biopsy are commonly used for lung cancer genomic testing.

Lung Cancer Genomic Testing uses a variety of tests, including EGFR, KRAS, and ALK testing. In some circumstances, a blood test (liquid biopsy) can detect tumor DNA in the bloodstream.  These tests can guide treatment decisions, predict cancer recurrence, and provide patients with a prognosis. It is crucial to remember that Lung Cancer Genomic Testing is not a standard aspect of the diagnosis for all lung cancer patients. However, for patients with NSCLC, it can be a useful tool for discovering focused treatment options and improving patient outcomes.

Market Dynamics

Global lung cancer genomic testing market drivers

Increasing incidence of lung cancer

The surging incidence of lung cancer is a significant driver for the global lung cancer genomic testing market. According to the World Health Organization (WHO), lung cancer remains the leading cause of cancer-related deaths globally, responsible for approximately 1.8 million deaths each year. This alarming prevalence is attributed to factors such as smoking, exposure to environmental pollutants, occupational hazards, and genetic predispositions. With the growing awareness of the importance of early detection, genomic testing is becoming increasingly essential in diagnosing and managing lung cancer.

Genomic testing allows for the identification of specific genetic mutations and alterations in lung cancer patients, enabling the development of targeted therapies that improve patient outcomes and survival rates. The advent of precision medicine, which tailors treatment plans to individual genetic profiles, further amplifies the need for comprehensive genomic testing. As the global burden of lung cancer continues to rise, the demand for advanced genomic testing technologies is expected to grow, driving market expansion.

Global lung cancer genomic testing market restraint

High costs and limited accessibility

Despite the advancements and benefits of genomic testing in lung cancer diagnosis and treatment, the high costs and limited accessibility of these technologies pose significant restraints. Comprehensive genomic profiling and next-generation sequencing (NGS) technologies require substantial financial investment in sophisticated equipment and skilled personnel. The cost of a single genomic test can range from hundreds to thousands of dollars, making it unaffordable for many patients, specifically in low- and middle-income countries.

Additionally, the healthcare infrastructure in these regions often lacks the necessary resources to support the widespread implementation of advanced genomic testing. Insurance coverage for these tests is frequently limited or non-existent, leading to high out-of-pocket expenses for patients. These financial and logistical barriers hinder the adoption of genomic testing, restricting its availability to a broader patient population. Consequently, the full potential of genomic testing in improving lung cancer diagnosis and treatment outcomes remains underutilized in many parts of the world.

Global lung cancer genomic testing market opportunities

Technological advancements

Technological advancements, particularly the advent of Next Generation Sequencing (NGS), have revolutionized lung cancer genomic testing. NGS enables comprehensive analysis of DNA and RNA, detecting mutations, gene expression, and epigenetic changes. This capability has been pivotal in identifying multiple genetic alterations in lung cancer, including EGFR, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, MET, RET, and PD-L1, crucial for targeted therapy decisions and improving patient outcomes. A 2023 study in the Journal of Thoracic Oncology noted a significant rise in NGS adoption over the last decade due to its ability to identify diverse mutations and guide personalized treatments.

Moreover, Memorial Sloan Kettering Cancer Center researchers introduced an AI-powered platform for lung cancer genomic data analysis. This innovation promises enhanced speed and accuracy in interpreting complex test results, facilitating more efficient treatment planning. These advancements underscore a growing market opportunity in the Global Lung Cancer Genomic Testing Market, driven by increasing demand for precise, personalized therapies supported by advanced genomic technologies. As such, the market is poised for further growth as healthcare providers integrate these technologies to improve diagnostic accuracy and therapeutic outcomes in lung cancer care.

Regional Analysis

Based on region, the global market is bifurcated into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. 

North america dominates the global market

North America holds the largest share of the global lung cancer genomic testing market and is poised for substantial growth during the forecast period. This leadership is driven by a high prevalence of lung cancer in the region, significantly increasing the demand for genomic testing to identify genetic abnormalities responsible for the disease. North America's advanced healthcare system, featuring state-of-the-art medical facilities and swift adoption of new technologies, further propels market expansion.

The U.S. government and private entities invest heavily in research and development, fostering the creation of advanced genomic testing tools. This investment landscape is bolstered by the presence of key industry players like Thermo Fisher Scientific, Illumina, and Qiagen, all of which contribute significantly to market growth. Moreover, the region's strong emphasis on personalized medicine, combined with high public awareness of its benefits, drives the increased utilization of genomic testing for lung cancer diagnosis and treatment. Additionally, initiatives such as the National Cancer Institute's efforts to enhance cancer research and the implementation of precision medicine programs underscore the region's commitment to advancing lung cancer treatment through genomic testing.

The Asia-Pacific region is poised to witness significant growth in the lung cancer genomic testing market, driven by several key factors. First, the region faces a rising burden of lung cancer due to factors such as increasing tobacco consumption, environmental pollution, and demographic changes. Countries like China, India, and Japan are experiencing a notable increase in lung cancer cases, contributing to the growing demand for advanced diagnostic and therapeutic solutions, including genomic testing. Additionally, improvements in healthcare infrastructure and rising healthcare expenditures in countries across Asia-Pacific are facilitating greater access to advanced medical technologies, including genomic testing.

Furthermore, government initiatives and healthcare reforms aimed at enhancing cancer care and promoting early detection are further propelling market growth. For instance, programs in countries like China and India focus on expanding cancer screening and treatment facilities, thereby boosting the adoption of genomic testing technologies. Moreover, increasing awareness among healthcare providers and patients about the benefits of personalized medicine is driving the uptake of genomic testing. Also, the Asia-Pacific region benefits from a large and diverse patient population, providing ample opportunities for market expansion and research collaborations. As regulatory frameworks evolve and investments in research and development continue to grow, the Asia-Pacific lung cancer genomic testing market is expected to flourish, offering new avenues for innovation and improved patient outcomes.

Segmental Analysis

The global market is bifurcated into type, technology, sample type, panel type, and end-user.

Based on the type, the global lung cancer genomic testing market is segmented into products and services.

The product segment is predicted to grow the most due to the rising demand for genomic testing in lung cancer detection and treatment. This is because genetic testing products, such as kits and reagents, are required for the examination of lung cancer samples. Furthermore, the advent of new and improved genomic testing technologies, such as next-generation sequencing (NGS) and polymerase chain reaction (PCR), is increasing demand for these goods. The surging prevalence of lung cancer, as well as the demand for individualized treatment options, are driving the expansion of the genetic testing products market. The genomic testing market encompasses a wide range of products, including NGS kits, PCR kits, and chemicals used to analyze lung cancer samples. These products are used to detect genetic alterations and biomarkers, which are required for the formulation of tailored treatment plans.

Based on the technology, the global lung cancer genomic testing market is segmented into polymerase chain reaction (PCR), next-generation sequencing (NGS), and fluorescence in situ hybridization.

The Polymerase Chain Reaction (PCR) technology category dominates the lung cancer genomic testing market. PCR is preferred because of its low cost and high sensitivity, which are critical for discovering lung cancer mutations that cause the disease. The capacity of PCR to amplify small amounts of DNA makes it an effective method for detecting specific genetic mutations associated with lung cancer, even in samples with low or degraded DNA. PCR can provide faster findings than other genomic testing methods. It is extremely sensitive and can identify even trace amounts of genetic material. PCR tests are typically less expensive than other genomic testing technologies, making them more affordable. These benefits lead to the dominant position of PCR in the market and its extensive use in lung cancer genetic testing.

Based on the sample type, the lung cancer genomic testing market is segmented into tissue biopsy and liquid biopsy.

Tissue biopsy has typically been the major sample type utilized for lung cancer genomic testing because it allows for direct and extensive investigation of tumor cells. However, recent technological improvements have made liquid biopsy a possible option. Liquid biopsy is the examination of circulating tumor cells (CTCs) or circulating tumor DNA (ctDNA) detected in the circulation. This non-invasive approach has several advantages over tissue biopsy, including easier access, a lower risk of complications, and the opportunity to track disease progression in real time. As a result, liquid biopsy is likely to drive growth in the Lung Cancer Genomic Testing market, gaining a major market share over the forecast period.

Based on the panel types, the lung cancer genomic testing market is segmented into multi-gene panels and single-gene panels.

Multi-Gene panels are projected to dominate the market because of their capacity to detect several genetic alterations and rearrangements at the same time. This is especially essential in lung cancer, where numerous genetic mutations can arise, and identifying them can aid in focused therapy options. Multi-gene panels, such as the MayoComplete Lung Cancer-Targeted Gene Panel with Rearrangement, Tumor, may detect 12 mutations and seven rearrangements. This complete method can provide prognostic and therapeutic solutions to patients, making it an important tool in personalized medicine. Furthermore, these panels can use lesser amounts of tissue for difficult-to-obtain specimens and offer microsatellite instability (MSI) status for immunotherapy recommendations.

Based on the end-user, the lung cancer genomic testing market is segmented into research organizations, hospitals/clinics, and diagnostic laboratories.

The Hospitals/Clinics segment is expected to dominate the Global Lung Cancer Genomic Testing Market. This dominance is driven by the rising demand for personalized medicine and an increasing number of patients seeking treatment in hospitals and clinics. Hospitals and clinics are equipped with advanced tools and infrastructure essential for conducting genetic testing, providing a convenient option for patients. Additionally, the increasing prevalence of lung cancer and the need for early and precise diagnosis further boost the demand for genomic testing in these settings. The ability of hospitals and clinics to integrate genomic testing into comprehensive cancer care plans enhances patient outcomes, reinforcing their leadership in the market.

Recent Developments

• February 2024- The Centers for Medicare & Medicaid Services have approved coverage for GatewaySeq, a genetic test developed by researchers at Washington University School of Medicine in St. Louis. This test can identify cancer mutations in solid tumors.
• May 2024- Invitae, a prominent medical genetics firm, has revealed its plans to present eight papers at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, scheduled to take place from May 31 to June 4, 2024. The reported clinical data highlights the significance of genetic testing in patients with diverse types of cancers, such as breast, gastric, prostate, and lung, in order to enhance the accuracy of management and therapy decisions.